Icon (NASDAQ:ICLR) Director Eugene Pacelli Mccague Sells 841 Shares

Icon Plc (NASDAQ:ICLR) Director Eugene Pacelli Mccague sold 841 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $164.29, for a total transaction of $138,167.89. Following the completion of the transaction, the director directly owned 3,811 shares in the company, valued at approximately $626,109.19. The trade was a 18.08% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Icon Stock Up 1.0%

ICLR stock traded up $1.59 during mid-day trading on Wednesday, reaching $167.17. 804,300 shares of the company traded hands, compared to its average volume of 1,385,101. The company has a quick ratio of 0.95, a current ratio of 0.95 and a debt-to-equity ratio of 0.23. The firm’s 50 day moving average price is $161.47 and its 200 day moving average price is $134.31. The stock has a market cap of $12.80 billion, a price-to-earnings ratio of 39.24, a P/E/G ratio of 6.88 and a beta of 1.21. Icon Plc has a fifty-two week low of $66.57 and a fifty-two week high of $203.91.

Icon (NASDAQ:ICLR) last posted its earnings results on Thursday, July 30th. The medical research company reported $2.56 earnings per share for the quarter, beating analysts’ consensus estimates of $2.55 by $0.01. The company had revenue of $2.06 billion for the quarter, compared to analyst estimates of $2 billion. Icon had a return on equity of 8.02% and a net margin of 3.99%.The company’s revenue for the quarter was up 2.3% on a year-over-year basis. During the same quarter last year, the company earned $3.26 earnings per share. As a group, equities research analysts predict that Icon Plc will post 9.57 EPS for the current fiscal year.

Key Headlines Impacting Icon

Here are the key news stories impacting Icon this week:

• Positive Sentiment: Icon’s latest quarterly results modestly exceeded expectations: adjusted EPS was $2.56 versus the $2.55 consensus, while revenue reached $2.06 billion, above the $2.00 billion estimate and up 2.3% year over year. Analysts expect approximately $9.57 in full-year EPS, providing a fundamental support for the stock.
• Positive Sentiment: Recent analyst actions have generally been constructive. BMO Capital Markets raised its price target to $187 and Mizuho increased its target to $190, both maintaining outperform ratings. The consensus target is $170.40, modestly above the latest trading level, although the overall consensus rating remains “Hold.”
• Positive Sentiment: Short interest is reported at zero shares, indicating no measurable bearish short-selling pressure or potential forced-selling overhang.
• Neutral Sentiment: CEO Barry Balfe sold 382 shares worth about $62,675, while CFO Nigel Clerkin sold 2,267 shares worth approximately $372,445. Directors John Climax and Linda Grais each sold 841 shares at about $164.29. The filings state that all transactions were made to cover tax-withholding obligations tied to vested equity awards, reducing their usefulness as a signal of declining confidence. SEC insider transaction filing
• Negative Sentiment: Despite the revenue beat, quarterly EPS fell from $3.26 a year earlier, and Icon’s reported net margin was only 3.99%. The stock also carries a high valuation, with a price-to-earnings ratio near 39 and a PEG ratio of 6.88, leaving it sensitive to any slowdown in clinical-research demand or earnings growth.

Analysts Set New Price Targets

Several analysts have recently issued reports on ICLR shares. Jefferies Financial Group reiterated a “buy” rating and issued a $165.00 target price on shares of Icon in a research note on Friday, May 29th. Barclays boosted their price target on shares of Icon from $160.00 to $175.00 and gave the stock an “equal weight” rating in a report on Thursday, June 25th. Royal Bank Of Canada raised shares of Icon from a “sector perform” rating to an “outperform” rating and upped their price objective for the stock from $126.00 to $185.00 in a research report on Thursday, June 25th. William Blair upgraded shares of Icon to a “strong-buy” rating in a research note on Thursday, July 30th. Finally, BMO Capital Markets lifted their target price on shares of Icon from $160.00 to $187.00 and gave the stock an “outperform” rating in a research report on Thursday, June 25th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $170.40.

Institutional Investors Weigh In On Icon

A number of hedge funds have recently made changes to their positions in the business. Jennison Associates LLC purchased a new position in shares of Icon in the fourth quarter valued at $123,542,000. Calamos Advisors LLC purchased a new stake in Icon during the 4th quarter worth about $4,829,000. OVERSEA CHINESE BANKING Corp Ltd bought a new position in Icon in the 4th quarter worth about $2,960,000. Hudson Edge Investment Partners Inc. boosted its stake in Icon by 29.7% in the 4th quarter. Hudson Edge Investment Partners Inc. now owns 260,449 shares of the medical research company’s stock worth $47,459,000 after purchasing an additional 59,710 shares during the period. Finally, Fisher Funds Management LTD grew its holdings in Icon by 19.0% during the 4th quarter. Fisher Funds Management LTD now owns 513,102 shares of the medical research company’s stock valued at $93,208,000 after buying an additional 82,019 shares in the last quarter. 95.61% of the stock is currently owned by institutional investors.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.